Pegylated interferon-α2b for local control of Langerhans cell sarcoma
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Dermatology"
DOI: 10.1684/ejd.2018.3411
Abstract: 835 cation as a CD8+ T-cell “lymphoproliferative disorder” is debated [7]. In contrast to PCAETCL, which requires aggressive polychemotherapy due to an ominous prognosis [2, 8], FUMHD is treated with systemic steroids, methotrexate [9], and/or… read more here.
Keywords: langerhans cell; pegylated interferon; cell sarcoma; control langerhans ... See more keywords